OSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

OSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Story continues below

On November 15, 2016, Osiris Therapeutics, Inc. (the “Company”) received an anticipated letter from The NASDAQ Stock Market (“NASDAQ”) noting that the Company had not filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (“Q3 2016 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) by its due date, in compliance with NASDAQ Listing Rule 5250(c)(1) (the “NASDAQ Listing Rule”) which requires that NASDAQ-listed companies file their periodic financial reports with the SEC on a timely basis.

As previously disclosed, on each of March 17, 2016, May 12, 2016 and August 12, 2016, the Company received a notification from NASDAQ that it had failed to comply with the NASDAQ Listing Rule by not timely filing with the SEC its Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”), its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (“Q1 2016 Form 10-Q”) and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (“Q2 2016 Form 10-Q”), respectively.

On November 10, 2016, the Company participated in a hearing before the NASDAQ Hearings Panel (the “Hearings Panel”) in connection with the Company’s late filings and the Company’s anticipated financial restatement relating to prior periods. At the hearing, the Company requested that the Hearings Panel grant the Company additional time to file its delinquent reports with the SEC and regain compliance with NASDAQ’s continued listing requirements, though any such additional time granted is at the sole discretion of the Hearings Panel and cannot be assured. The Company is continuing to work diligently to complete its previously announced accounting reviews, restatements of prior period financial statements, transition to a new independent registered public accounting firm and 2015 audit so that it will be in a position to bring its SEC filings up to date.  However, there can be no assurance regarding the timing or ultimate outcome of this process or the ability of the Company to successfully maintain its NASDAQ listing.

On November 21, 2016, the Company issued a press release regarding the foregoing matters.  A copy of the press release is filed herewith as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Forward Looking Statements

Certain matters discussed in this Current Report on Form 8-K constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to management. Such forward-looking statements include statements regarding the timing or outcome of the NASDAQ listing qualification deficiency process or the ability of the Company to successfully maintain its NASDAQ listing, the timing or outcome of the restatements, including the materiality, significance, nature, subject matter, timing or quantitative effects of the Company’s restated financial statements, the transition to a new independent registered public accounting firm, the timing of the audit of the Company’s 2015 financial statements or the timing of the filing of the Company’s 2015 Form 10-K, Q1 2016 Form 10-Q, Q2 2016 Form 10-Q or Q3 2016 Form 10-Q. We caution you not to place undue reliance on any such forward-looking statements. Several factors could cause actual results to differ materially from those expressed in or contemplated by the forward-looking statements. Such factors include, but are not limited to, include the identification of additional errors in the restated financial statements, changes in the scope or focus of the accounting adjustments, the risk that additional information may arise prior to the expected filing with the SEC of the restated financial statements, the preparation of our restated financial statements or other subsequent events that would require us to make additional

adjustments. Other risk factors affecting the Company are discussed in detail in the Company’s filings with the SEC, including its Annual Reports on Form 10-K. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release, dated November 21, 2016


About OSIRIS THERAPEUTICS, INC. (NASDAQ:OSIR)

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

OSIRIS THERAPEUTICS, INC. (NASDAQ:OSIR) Recent Trading Information

OSIRIS THERAPEUTICS, INC. (NASDAQ:OSIR) closed its last trading session down -0.04 at 6.54 with 124,177 shares trading hands.

An ad to help with our costs